Yabao Pharmaceutical Group Co Ltd Capital Reinvestment Ratio
Yabao Pharmaceutical Group Co Ltd capital reinvestment ratio. Yabao Pharmaceutical Group Co Ltd (600351) has a Capital Reinvestment Ratio of 0.06x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥129.49 Million) in capital expenditures (CN¥7.58 Million). Check 600351 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Yabao Pharmaceutical Group Co Ltd (2001–2024)
Capital reinvestment ratio of Yabao Pharmaceutical Group Co Ltd from 2001 to 2024. This chart tracks Yabao Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 22 annual periods. Also explore net asset growth rate of Yabao Pharmaceutical Group Co Ltd to track the company's year-over-year net asset growth rate.
Yabao Pharmaceutical Group Co Ltd Capital Reinvestment Ratio by Year (2001–2024)
Yabao Pharmaceutical Group Co Ltd capital reinvestment ratio by year from 2001 to 2024. For the full cash flow conversion analysis, see 600351 operating cash flow.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | CN¥471.69 Million | CN¥34.66 Million | ▼ -63.4% |
| 2023 | 0.20x | CN¥497.55 Million | CN¥99.86 Million | ▲ +48.5% |
| 2022 | 0.14x | CN¥460.46 Million | CN¥62.23 Million | ▼ -37.8% |
| 2021 | 0.22x | CN¥437.50 Million | CN¥95.05 Million | ▲ +31.7% |
| 2020 | 0.17x | CN¥380.96 Million | CN¥62.87 Million | ▼ -55.3% |
| 2019 | 0.37x | CN¥425.17 Million | CN¥157.09 Million | ▲ +131.8% |
| 2018 | 0.16x | CN¥426.60 Million | CN¥68.01 Million | ▼ -74.0% |
| 2017 | 0.61x | CN¥161.73 Million | CN¥99.34 Million | ▲ +13.4% |
| 2016 | 0.54x | CN¥155.95 Million | CN¥84.46 Million | ▼ -23.6% |
| 2015 | 0.71x | CN¥143.47 Million | CN¥101.68 Million | ▼ -27.2% |
| 2014 | 0.97x | CN¥178.63 Million | CN¥173.84 Million | ▼ -44.2% |
| 2013 | 1.74x | CN¥56.80 Million | CN¥99.02 Million | ▼ -40.6% |
| 2011 | 2.94x | CN¥40.73 Million | CN¥119.56 Million | ▼ -70.9% |
| 2010 | 10.09x | CN¥18.57 Million | CN¥187.30 Million | ▲ +1278.1% |
| 2009 | 0.73x | CN¥368.56 Million | CN¥269.82 Million | ▼ -48.9% |
| 2008 | 1.43x | CN¥102.90 Million | CN¥147.56 Million | ▲ +384.1% |
| 2007 | 0.30x | CN¥105.69 Million | CN¥31.31 Million | ▼ -92.1% |
| 2006 | 3.77x | CN¥11.59 Million | CN¥43.70 Million | ▼ -8.7% |
| 2005 | 4.13x | CN¥26.40 Million | CN¥108.95 Million | ▲ +62.3% |
| 2004 | 2.54x | CN¥79.73 Million | CN¥202.81 Million | ▲ +125.7% |
| 2002 | 1.13x | CN¥24.29 Million | CN¥27.38 Million | ▲ +15.4% |
| 2001 | 0.98x | CN¥23.59 Million | CN¥23.04 Million | — |